T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase

Handbook of Experimental Pharmacology

Volumn 188, Issue , 2009, Pages 165-196

  Mellor, Andrew L ^a   Kahler, David J ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; ALLOANTIGEN; AMINO ACID; ANTIOXIDANT; BRASSININ; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; EXIGUAMINE A; GARVEIA ANNULATA EXTRACT; HISTONE DEACETYLASE INHIBITOR; HYDROGEN PEROXIDE; INDOLE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; N METHYL N' 9 PHENANTHRENYLIMIDODICARBONIMIDIC DIAMIDE; NATURAL PRODUCT; NITRIC OXIDE; NSC 401366; PARA COUMARIC ACID; PEROXYNITRITE; PYRROLIDINE DITHIOCARBAMATE; REAGENT; ROSMARINIC ACID; TRYPTOPHAN; TRYPTOPHAN DERIVATIVE; TRYPTOPHAN TRANSFER RNA LIGASE; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEBULARINE;

ADJUVANT THERAPY; ALLERGY; AMINO ACID TRANSPORT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CHRONIC DISEASE; DENDRITIC CELL; DRUG MEGADOSE; ENZYMOLOGY; FETUS DEVELOPMENT; GENE EXPRESSION; GRAFT SURVIVAL; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; CELL DIFFERENTIATION; ENZYME INDUCTION; GENETICS; IMMUNOCOMPETENCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY;

ANIMALS; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; DENDRITIC CELLS; ENZYME INDUCTION; HUMANS; IMMUNOCOMPETENCE; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 60549086844     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-71029-5-8     Document Type: Review

References (142)

1. Abel K, Wang Y et al (2005) Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol 12:606-621
2. Agaugue S, Perrin-Cocon L et al (2006) 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 177:2061-2071
3. Asselin-Paturel C, Boonstra A et al (2001) Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2:1144-1150
4. Asselin-Paturel C, Brizard G et al (2003) Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171:6466-6477
5. Baban B, Hansen AM et al (2005) A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 17:909-919
6. Ball HJ, Sanchez-Perez A et al (2007) Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396:203-213
7. Banerjee T, Duhadaway JB et al (2007) A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27: 2851-2857
8. Basu GD, Tinder TL et al (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177:2391-2402
9. Blackwell SE, Krieg AM (2003) CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol 170: 4061-4068
10. Boasso A, Herbeuval JP et al (2005) Regulation of indoleamine 2,3-dioxygenase and tryptophanyltRNA- synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 105:1574-1581
11. Boasso A, Herbeuval JP et al (2007) HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109:3351-3359
12. Boasso A, ShearerGM (2007) How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab 8:217-223
13. Booth JS, Nichani AK et al (2007) Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet Immunol Immunopathol 115:24-34
14. Brastianos HC, Vottero E et al (2006) Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 128:16046-16047
15. Braun D, Longman RS et al (2005) A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106:2375-2381
16. Burke F, Knowles RG et al (1995) The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer 60:115-122
17. Cady SG, Sono M (1991) 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291:326-333
18. Chelbi-Alix MK,Wietzerbin J (2007) Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 89:713-718
19. Cravens PD, Hayashida K et al (2007) Human peripheral blood dendritic cells and monocyte subsets display similar chemokine receptor expression profiles with differential migratory responses. Scand J Immunol 65:514-524
20. Dai W, Gupta SL (1990) Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferongamma and interferon-alpha. J Biol Chem 265:19871-19877
21. Decker T, MullerMet al (2005) The Yin and Yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5:675-687
22. Dong J, Qiu H et al (2000) Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell 6:269-279
23. Duluc D, Delneste Y et al (2007) Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110:4319-4330
24. Dzionek A, Fuchs A et al (2000) BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood. J Immunol 165:6037-6046
25. Fallarino F, Asselin-Paturel C et al (2004) Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173:3748-3754
26. Fallarino F, Gizzi S et al (2007) Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr Drug Metab 8:209-216
27. Fallarino F, Grohmann U et al (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4:1206-1212
28. Fallarino F, Grohmann U et al (2002a) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9:1069-1077
29. Fallarino F, Vacca C et al (2002b) Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 14:65-68
30. Fallarino F, Grohmann U et al (2006) the combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor {zeta}-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752-6761
31. Fallarino F, Orabona C et al (2005) Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int Immunol 17:1429-1438
32. Finger EB, Bluestone JA (2002) When ligand becomes receptor[-]tolerance via B7 signaling on DCs. Nat Immunol 3:1056-1057
33. Friberg M, Jennings R et al (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151-155
34. Frumento G, Rotondo R et al (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196:459-468
35. Fujigaki H, Saito K et al (2006) Nitration and inactivation of IDO by peroxynitrite. J Immunol 176:372-379
36. Furset G, Floisand Y et al (2007) Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology 123:263-271
37. Gaspari P, Banerjee T et al (2006) Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 49:684-692
38. Grage-Griebenow E, Loseke S et al (2007) Anti-BDCA-4 (neuropilin-1) antibody can suppress virus-induced IFN-alpha production of plasmacytoid dendritic cells. Immunol Cell Biol 85:383-390
39. Grohmann U, Bianchi R et al (2003) Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol 171:2581-2587
40. Grohmann U, Fallarino F et al (2001a) IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol 167:708-714
41. Grohmann U, Fallarino F et al (2001b) CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol 166:277-283
42. Grohmann U, Orabona C et al (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3:1097-1101
43. Grohmann U, Volpi C et al (2007) Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 13:579-586
44. Guillonneau C, Hill M et al (2007) CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 117:1096-1106
45. Hackstein H, Thomson AW (2004) Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4:24-34
46. Harding HP, Zhang Y et al (2003) An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11:619-633
47. Hayashi T, Beck L et al (2004) Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 114:270-279
48. Hayashi T, Mo JH et al (2007) 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci USA 104:18619-18624
49. Hilkens CM, Schlaak JF et al (2003) Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 171:5255-5263
50. Hill JA, FeuererMet al (2007a) Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27:786-800
51. Hill M, Tanguy-Royer S et al (2007b) IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 37:3054-3062
52. Hochrein H, O'Keeffe M et al (2002) Human and mouse plasmacytoid dendritic cells. Hum Immunol 63:1103-1110
53. Honda K, Yanai H et al (2005) IRF-7 is the master regulator of type-I interferon-dependent immuneresponses. Nature 434:772-777
54. Hou DY, Muller AJ et al (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67: 792-801
55. Hunt JS (2006) Stranger in a strange land. Immunol Rev 213:36-47 Hwu P, Du MX et al (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596-3599
56. Janke M, Witsch EJ et al (2006) Eminent role of ICOS costimulation for T cells interacting with plasmacytoid dendritic cells. Immunology 118:353-360
57. Jasperson LK, Bucher C et al (2007) Indoleamine 2,3-dioxygenase is a critical regulator of acute GVHD lethality. Blood 111:3257-3265
58. Jeong YI, Jung ID et al (2007) (-)-Epigallocatechin gallate suppresses indoleamine 2,3- dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem Biophys Res Commun 354:1004-1009
59. Johnson LM, Scott P (2007) STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major. J Immunol 178:7259-7266
60. Jung ID, Lee CM et al (2007) Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBS Lett 581:1449-1456
61. Keith IM, BrownfieldMS (1985) Evidence for presence of kynurenine in lung and brain of neonate hamsters. Histochemistry 83:465-471
62. Kim SI, Jeong YI et al (2007) p-Coumaric acid inhibits indoleamine 2, 3-dioxygenase expression in murine dendritic cells. Int Immunopharmacol 7:805-815
63. Lee GK, Park HJ et al (2002) Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107:452-460
64. Lee HJ, Jeong YI et al (2007) Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochem Pharmacol 73:1412-1421
65. Lee JR, Dalton RR et al (2003) Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 83:1457-1466
66. Liao M, Pabarcus MK et al (2007) Impaired dexamethasone-mediated induction of tryptophan 2,3- dioxygenase in heme-deficient rat hepatocytes: Translational control by a hepatic eIF2{alpha} kinase, the heme-regulated inhibitor (HRI). J Pharmacol Exp Ther 33:979-989
67. Liu H, Xue ZT et al (2007) Low dose Zebularine treatment enhances immunogenicity of tumorcells. Cancer Lett 257:107-115
68. Lob S, Konigsrainer A et al (2007) Levo- but not dextro-1-methyl tryptophan abrogates the IDOactivity of human dendritic cells. Blood 111:2152-2154
69. Mahnke K, Johnson TS et al (2007) Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 46:159-167
70. Manlapat AK, Kahler DJ et al (2007) Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol 37: 1064-1071
71. Martinson JA, Tenorio AR et al (2007) Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology 120:526-535
72. Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20:469-473
73. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762-774
74. Mellor AL, Munn DH (2008) Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8:74-80
75. Mellor AL, Baban B et al (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171:1652-1655
76. Mellor AL, Chandler P et al (2004) Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 16:1391-1401
77. Mellor AL, Baban B et al (2005) Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175:5601-5605
78. Metz R, Duhadaway JB et al (2007) Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan. Cancer Res 67:7082-7087
79. Morelli AE, Thomson AW(2007) Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol advanced online publication 7:610-621
80. Mrass P, Weninger W (2006) Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 213:195-212
81. Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev 213:146-158
82. Munn DH, Pressey J et al (1996) Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion. J Immunol 156:523-532
83. Munn DH, Zhou M et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193
84. Munn DH, Shafizadeh E et al (1999) Inhibition of T cell proliferation by macrophage tryptophancatabolism. J Exp Med 189:1363-1372
85. Munn DH, Sharma MD et al (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867-1870
86. Munn DH, Sharma MD et al (2004a) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-90
87. Munn DH, Sharma MD et al (2004b) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172:4100-4110
88. Munn DH, Mellor AL et al (2005a) Dendritic cells have the option to express IDO-mediated suppression or not. Blood 105:2618
89. Munn DH, Sharma MD et al (2005b) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22:633-642
90. Myint AM, Kim YK (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61:519-525
91. Nair MP, Schwartz SA et al (2004) Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J Neuroimmunol 157:56-60
92. Orabona C, Belladonna ML et al (2005a) Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 174:6582-6586
93. Orabona C, Tomasello E et al (2005b) Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur J Immunol 35:3111-3118
94. Ou X, Cai S et al (2007) Enhancement of dendritic cell-tumor fusion vaccine potency byindoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol 134:525-533
95. Paguirigan AM, Byrne GI et al (1994) Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures. Infect Immun 62: 1131-1136
96. Patterson S, Rae A et al (2001) Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J Virol 75:6710-6713
97. Peggs KS, Quezada SA et al (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213
98. Penberthy WT (2007) Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab 8:245-266
99. Pereira A, Vottero E et al (2006) Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod 69:1496-1499
100. Pestka S, Krause CD et al (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8-32
101. Peters N, Sacks D (2006) Immune privilege in sites of chronic infection: leishmania and regulatory T cells. Immunol Rev 213:159-179
102. Peterson AC,MigawaMT, Martin MJ, Hamaker LK, Czerwinski KM, ZhangW, Arend RA, Fisette PL, Ozaki Y, Will JA, Brown RR, Cook JM (1994) Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase. Med Chem Res:531-544
103. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375-386
104. Platten M, Ho PP et al (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310:850-855
105. Poljak A, Grant R et al (2006) Inhibition of indoleamine 2,3 dioxygenase activity by H2O2. Arch Biochem Biophys 450:9-19
106. Popov A, Abdullah Z et al (2006) Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest 116: 3160-3170
107. Puthalakath H, O'Reilly LA et al (2007) ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129:1337-1349
108. Reddy P, Sun Y et al (2007) 35: Histone deacetylase inhibitors induce indoleamine 2,3-dioxygenase and modulate dendritic cell functions. Biol Blood Marrow Transplant 13: 15-16 Reis e Sousa C (2006) Dendritic cells in a mature age. Nat Rev Immunol 6:476-483
109. Roberts TL, Sweet MJ et al (2005) Cutting Edge: Species-Specific TLR9-Mediated Recognition of CpG and Non-CpG Phosphorothioate-Modified Oligonucleotides. J Immunol 174:605-608
110. Rodriguez PC, Quiceno DG et al (2007) L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109:1568-1573
111. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345-352
112. Sakurai K, Zou JP et al (2002) Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 129:186-196
113. Salter M, Hazelwood R et al (1995) The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol 49: 1435-1442
114. Samelson-Jones BJ, Yeh SR (2006) Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 45:8527-8538
115. Saxena V, Ondr JK et al (2007) The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol 179:5041-5053
116. Seymour RL, Ganapathy V et al (2006) A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol 80:1320-1327
117. Sharma MD, Baban B et al (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117:2570-2582
118. Shevach EM, DiPaolo RA et al (2006) The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells. Immunol Rev 212:60-73
119. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7:19-30
120. Sotero-Esteva WD, Wolfe D et al (2000) An indoleamine 2,3-dioxygenase-negative mutant is defective in stat1 DNA binding: differential response to IFN-gamma and IFN-alpha. J Interferon Cytokine Res 20:623-632
121. Steinman RM, Hawiger D et al (2003) Dendritic cell function in vivo during the steady state: a rolein peripheral tolerance. Ann N Y Acad Sci 987:15-25
122. Sugimoto H, Oda S et al (2006) Crystal structure of human indoleamine 2,3-dioxygenase: catalyticmechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 103:2611-2616
123. Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3- dioxygenase, and tryptophan catabolism. Faseb J 5:2516-2522
124. Terness P, Bauer TM et al (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3- dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196:447-457
125. Terness P, Chuang JJ et al (2005) Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood 105:2480-2486
126. Thomas SR, Stocker R (1999) Antioxidant activities and redox regulation of interferon-gammainducedtryptophan metabolism in human monocytes and macrophages. Adv Exp Med Biol 467:541-552
127. Thomas SR, Mohr D et al (1994) Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 269:14457-14464
128. Thomas SR, Salahifar H et al (2001) Antioxidants inhibit indoleamine 2,3-dioxygenase in IFNgamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 166:6332-6340
129. Thomas SR, Terentis AC et al (2007) Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 282:23778-23787
130. Thornton AM, Piccirillo CA et al (2004) Activation requirements for the induction of CD4 + CD25+ T cell suppressor function. Eur J Immunol 34:366-376
131. Travers MT, Gow IF et al (2004) Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta 1661:106-112
132. van Boxel-Dezaire AH, Rani MR et al (2006) Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25:361-372
133. Vollmer J, Jurk M et al (2004a) CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res 10:431-438
134. Vollmer J, Weeratna R et al (2004b) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251-262
135. von Bergwelt-Baildon MS, Popov A et al (2006) CD25 and indoleamine 2,3-dioxygenase are upregulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108:228-237
136. Vottero E, Balgi A et al (2006) Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotechnol J 1:282-288
137. Wek RC, Jiang HY et al (2006) Coping with stress: eIF2 kinases and translational control. BiochemSoc Trans 34:7-11
138. Wingender G, Garbi N et al (2006) Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 36:12-20
139. Wirleitner B, Neurauter G et al (2004) Down-regulatory effect of N-chlorotaurine on tryptophandegradation and neopterin production in human PBMC. Immunol Lett 93:143-149
140. Yamamoto S, Hayaishi O (1967) Tryptophan Pyrrolase of Rabbit Intestine. d- and l-tryptophancleaving enzyme or enzymes. J. Biol. Chem. 242:5260-5266
141. Yasui H, Takai K et al (1986) Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 83:6622-6626
142. Youn J, Lee KH et al (2003) Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis. J Rheumatol 30:1203-1207